Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
4 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Potential Role of Circulating PD-L1+ Leukocytes as a Predictor of Response to Anti-PD-(L)1 Therapy in NSCLC Patients.
Biomedicines. 2024 Apr 25;12(5):958. doi: 10.3390/biomedicines12050958.
Biomedicines. 2024.
PMID: 38790920
Free PMC article.
Kinetics of IFNγ-Induced Cytokines and Development of Immune-Related Adverse Events in Patients Receiving PD-(L)1 Inhibitors.
Alserawan L, Mulet M, Anguera G, Riudavets M, Zamora C, Osuna-Gómez R, Serra-López J, Barba Joaquín A, Sullivan I, Majem M, Vidal S.
Alserawan L, et al. Among authors: serra lopez j.
Cancers (Basel). 2024 May 1;16(9):1759. doi: 10.3390/cancers16091759.
Cancers (Basel). 2024.
PMID: 38730712
Free PMC article.
Item in Clipboard
Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse Events.
Alserawan L, Anguera G, Zamora Atenza C, Serra López J, Martínez-Martínez L, Riudavets Melià M, Sullivan I, Barba Joaquin A, Majem Tarruella M, Vidal S.
Alserawan L, et al. Among authors: serra lopez j.
Int J Mol Sci. 2022 Oct 20;23(20):12641. doi: 10.3390/ijms232012641.
Int J Mol Sci. 2022.
PMID: 36293498
Free PMC article.
Item in Clipboard
The integration of systemic and tumor PD-L1 as a predictive biomarker of clinical outcomes in patients with advanced NSCLC treated with PD-(L)1blockade agents.
Zamora Atenza C, Anguera G, Riudavets Melià M, Alserawan De Lamo L, Sullivan I, Barba Joaquin A, Serra Lopez J, Ortiz MA, Mulet M, Vidal S, Majem M.
Zamora Atenza C, et al. Among authors: serra lopez j.
Cancer Immunol Immunother. 2022 Aug;71(8):1823-1835. doi: 10.1007/s00262-021-03107-y. Epub 2022 Jan 5.
Cancer Immunol Immunother. 2022.
PMID: 34984538
Free PMC article.
Item in Clipboard
Cite
Cite